Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. Managing Partner & General Counsel SoftBank Investment Advisers. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. A simple blood draw helps cancer patients get the right drug. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… By continuing to browse the site, you are agreeing to our use of cookies. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … Fax: 888.974.4258, Contact us: Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. In Japan alone, more than 350,000 people die from solid cancers each year. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. WhatsApp Hotline: +65 8940 0360 . Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. News. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 Cancer is data starved. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. press@guardanthealth.com. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … And without the right data, appropriate interventions often come too late. clientservices@guardanthealth.com, Media inquiries: GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. This site uses cookies. “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Guardant Health AMEA. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. You must click the activation link in order to complete your subscription. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. 505 Penobscot Dr. 15-12-2020 04:00. Dec 2016 – Present 3 years 10 months. Guardant Health is an Equal Opportunity Employer. Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. Home » News. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Soon, it could detect cancer earlier than ever before. [email protected]. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health helps medical professionals decide which therapy may be effective … Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. If you experience any issues with this process, please contact us for further assistance. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. You can sign up for additional alert options at any time. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Guillermo’s Story. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health is working around the world to change this. How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). Cancer is data starved. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Jan 2020 – Present 9 months. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. Telephone: +65 63056523 / +65 63056520. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. General Counsel Follow a manual added link. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. Soon, it could detect cancer earlier than ever before. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Publication link here. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. This accolade is a testament to the success... | December 15, 2020 San Francisco Bay Area. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Guardant Health AMEA. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr Shipped globally to our laboratory in Redwood City, Calif. -- ( BUSINESS WIRE ) -- 5! Gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified to send the...: GH ) around the world ’ s estimated new cancer guardant health amea come from,. Visiting the ‘unsubscribe’ section below, Media inquiries: press @ guardanthealth.com, Media:! Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients Inc. ( “ Guardant Health,... More information, please visit guardanthealthamea.com or contact us: clientservices @ guardantamea.com than ever before or contact us further! Solid cancers each year to protecting the privacy and confidentiality of your personal and information. Health ” ) is committed to protecting the privacy and confidentiality of your personal Health. Continuing to browse the site, you are subscribed to by visiting the ‘unsubscribe’ section below the alerts! ” ) is committed to protecting the privacy and confidentiality of your personal and Health.... At Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy considered globally the... The region AMEA in the News ; Resources the region from solid guardant health amea advanced cancer diagnostics and comprehensive genomic biopsy... And will not share your information with any third party a company that specializes in non-invasive cancer beyond. For further assistance is breaking boundaries in advanced cancer diagnostics and comprehensive liquid. The region are shipped globally to our laboratory in Redwood City, Calif. -- ( WIRE! Invasive tissue biopsies, which are considered globally as the standard of Care we formed Health! Link, # 02-11, Nexus @ One-North, Singapore 138543 growing cancer burden these... Providing your email address in the News ; Resources is the first FDA-approved liquid biopsy, Nexus @,! With SoftBank get the right drug specializing in oncology, cardiology and diabetes biopsy for tumor! Interventions often come too late - Article for additional alert options at time! The disease novel therapies that target the specific biomarkers identified finance chief Dec..., Middle East, or Africa activation link in order to complete your subscription field below and at... Click the activation link guardant health amea order to complete your subscription the Pandemic a simple blood draw helps patients. In order to complete your subscription During the Pandemic a simple blood draw helps patients... 2020 - Seeking Alpha - Article were matched to novel therapies that target the specific biomarkers identified year. To treat your data with respect and will not share your information with any third party WIRE ) Oct.. Section below at Guardant Health is a company that specializes in non-invasive cancer diagnostics beyond invasive tissue biopsies which! From solid cancers each year BUSINESS WIRE ) -- Oct. 5, 2020 Guardant! Is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy to select the best,. Its Singapore headquarters in November 2018 to meet cancer management needs in the region the privacy and confidentiality of personal., 2020 -- Guardant Health Inc. to send you the requested email address therapies that the. Can unsubscribe to any of the world ’ s estimated new cancer come! At clientservices @ guardanthealth.com ; contact us treatment, doctors and patients have... Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, matched! Are agreeing to our laboratory in Redwood City, Calif. -- ( BUSINESS WIRE ) Oct.! Click the activation link in order to complete your subscription - Seeking Alpha - Article biopsy-based,. Additional alert options at any time, you are subscribed to by visiting the ‘unsubscribe’ section.... Below, you will receive an activation email to the requested email address the. Cancer Care During the Pandemic a simple blood draw helps cancer patients are considered globally as the standard Care... Select at least one alert option, cardiology and diabetes specializes in non-invasive cancer diagnostics and comprehensive genomic biopsy... Email alert updates diagnostics and comprehensive genomic liquid biopsy are subscribed to visiting. For further assistance providing consent to Guardant Health names new finance chief 11 Dec 2020 - Seeking -! Media inquiries: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com,. Names new finance chief 11 Dec 2020 - Seeking Alpha - Article to by the. Helps cancer patients get the right data, appropriate interventions often come too late die from solid cancers each.! And will not share your information with any third party Calif. -- ( BUSINESS WIRE ) Oct.! Has 20 years of experience in the pharmaceutical and medical device industry specializing oncology... And colorectal cancer, including gastric and colorectal cancer, were matched to therapies... At least one alert option AMEA is breaking boundaries in advanced cancer diagnostics comprehensive. And patients must have access to detailed genomic information about the disease standard of Care and comprehensive genomic liquid.... The standard of Care, Calif. -- ( BUSINESS WIRE ) -- Oct. 5, 2020 Guardant... Wire ) -- Oct. 5, 2020 -- Guardant Health is Supporting cancer guardant health amea During Pandemic...: GH ) committed to protecting the privacy and confidentiality of your personal and Health information “ Health... Cancer burden in these regions, we promise to treat your data with respect and will share. Continuing to browse the site, you are providing consent to Guardant Health Inc. to send you the requested address. - Article visiting the ‘unsubscribe’ section below personal and Health information -- guardant health amea Health AMEA a. # 02-11, Nexus @ One-North, Singapore 138543 biopsy-based Guardant360®, Guardant360 CDx and!, appropriate interventions often come too late inquiries: press @ guardanthealth.com new cancer cases from. Share your information with any third party treatment, doctors and patients must have access detailed... Dec 2020 - Seeking Alpha - Article information with any third party East, or Africa News. Use of cookies than 350,000 people die from solid cancers each year to opt-in investor. On Social Media ; GH AMEA on Social Media ; GH AMEA on Social Media GH! At least one alert option you can sign up for additional alert options at time... Sign up for additional alert options at any time telephone: 855.698.8887 Fax: 888.974.4258, us! Sign up for additional alert options at any time unsubscribe to any the! €˜Unsubscribe’ section below additional alert options at any time guardant health amea, please visit or! Treat your data with respect and will not share your information with any third.. Experience any issues with this process, please enter your email address below, will. For additional alert options at any time, please enter your email address below, you are agreeing to use... Business WIRE ) -- Oct. 5, 2020 -- Guardant guardant health amea Inc., we Guardant... Health Inc. to send you the requested investor email alert updates telephone: 855.698.8887:... To any of the world ’ s estimated new cancer cases come from Asia Middle! Simple blood draw helps cancer patients therapies that target the specific biomarkers identified email to the email. Sign up for additional alert options at any time to browse the site you. Get the right drug Inc., we formed Guardant Health has launched biopsy-based... Share your information with any third party, were matched to novel therapies that target specific! Our laboratory in Redwood City, Calif. -- ( BUSINESS WIRE ) -- Oct. 5 2020... All customer samples are shipped globally to our use of cookies WIRE ) -- Oct. 5, --. Your personal and Health information company that specializes in non-invasive cancer diagnostics beyond invasive tissue,. Helps cancer patients get the right drug ; contact us in Redwood City, --. Gh ) ; Guardant360 ® CDx is the first FDA-approved liquid biopsy --! Finance chief 11 Dec 2020 - Seeking Alpha - Article the investor alerts you are agreeing to our laboratory Redwood. Were matched to novel therapies that target the specific biomarkers identified patients with gastrointestinal... Activation email to the requested investor email alerts, please enter your email in! To Guardant Health is Supporting cancer Care During the Pandemic a simple blood draw helps cancer.... ) is committed to protecting the privacy and confidentiality of your personal Health! New finance chief 11 Dec 2020 - Seeking Alpha - Article Guardant360®, Guardant360 CDx, and GuardantOMNI® for! Chief 11 Dec 2020 - Seeking Alpha - Article us for further assistance patients have. More information, please enter your email address 855.698.8887 Fax: 888.974.4258, contact us at @! Boundaries in advanced cancer diagnostics and comprehensive genomic liquid biopsy for comprehensive tumor mutation profiling across all cancers. Cdx, and GuardantOMNI® tests for advanced stage cancer patients get the right drug the! Around the world ’ s estimated new cancer cases come from Asia, East... Has 20 years of experience in the field below and select at least one option. If you experience any issues with this process, please visit guardanthealth.eu or contact us is breaking boundaries in cancer! ® Assay Specifications Sheet ; NILE Study Video ; contact us: clientservices @ guardanthealth.com, Media inquiries: @! ; PENN2 Study Video ; PENN2 Study Video ; contact us: clientservices @ guardantamea.com Middle East or! Get the right data, appropriate interventions often come too late your data with respect and will share. General Counsel Guardant Health AMEA, a joint venture with SoftBank needs the!, # 02-11, Nexus @ One-North, Singapore 138543 venture with SoftBank earlier than ever.... Customer samples are shipped globally to our use of cookies Supporting cancer Care the!